Cookies disclaimer

I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.

Exploring tumour biopsies: a novel pre-clinical model to assess patient response to specific therapeutics

   1597

Scientific Reports - Although an array of new therapeutics has emerged for the treatment of colorectal cancer, their use is significantly impacted by variability in patient response. Better pre-clinical models could substantially improve efficacy as it may allow stratification of patients into the correct treatment regime.

In this study, a group of British researchers explored acute, ex vivo treatment of fresh, surgically resected human colorectal tumour biopsies as a novel pre-clinical model for identifying patient response to specific therapeutics.

These data suggest that acute treatment of small tumour biopsies is worthy of further exploration as a pre-clinical model to evaluate colorectal cancer response to novel therapies.

 

Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib

 

Authors: Sonia M. Novo, Stephen R. Wedge & Lesley A. Stark

Scientific Reports - doi:10.1038/s41598-017-12222-9 -  20 September 2017

Exploring tumour biopsies: a novel pre-clinical model to assess patient response to specific therapeutics

Click here to read the full article 


Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now

×